CN114917309A - Dai medicine composition for external use for treating gouty arthritis and application - Google Patents
Dai medicine composition for external use for treating gouty arthritis and application Download PDFInfo
- Publication number
- CN114917309A CN114917309A CN202210200870.8A CN202210200870A CN114917309A CN 114917309 A CN114917309 A CN 114917309A CN 202210200870 A CN202210200870 A CN 202210200870A CN 114917309 A CN114917309 A CN 114917309A
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine composition
- gouty arthritis
- dai medicine
- dai
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/59—Menispermaceae (Moonseed family), e.g. hyperbaena or coralbead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses an external Dai medicine composition for treating gouty arthritis and application thereof, wherein the Dai medicine composition is prepared from the following Chinese medicinal raw materials in parts by weight: 15-35 parts of swertia mileensis, 10-30 parts of turmeric, 10-30 parts of anemone, 15-35 parts of eclipta alba and 15-35 parts of plantain. The Dai medicine materials with different components and different drug properties are scientifically matched, and the Dai medicine materials have the effects of promoting blood circulation, removing blood stasis, dredging collaterals, relieving swelling, resisting inflammation, relieving pain, relaxing tendons and activating collaterals, and can have a good clinical curative effect on tissue swelling caused by gouty arthritis. The invention adopts an external method to treat local inflammatory reaction, can be absorbed through skin, ensures that the effective concentration of local drugs is obviously higher than blood concentration, exerts obvious curative effect, has small side effect and is worthy of clinical popularization and application.
Description
Technical Field
The invention belongs to the field of medicines, and particularly relates to an external Dai medicine composition for treating gouty arthritis and application thereof.
Background
Gouty Arthritis (GA), referred to as gout for short, is arthritis in which monosodium urate (MSU) precipitates on joints and surrounding tissues, is mainly related to purine metabolic disorder and/or uric acid excretion disorder, and belongs to the category of metabolic rheumatism. Acute gouty arthritis refers to arthritis caused by acute attack of gout, which is mainly clinically manifested as sudden joint swelling and pain, which is frequently seen in the 1 st metatarsophalangeal joint and severe pain, and can cause joint dysfunction in severe cases.
Modern medicine for treating gouty arthritis is mainly used for relieving local inflammation, controlling uric acid metabolism and inhibiting urate crystal deposition. The specific purpose is staged treatment, the autumn water alkaloid, the non-steroidal anti-inflammatory drug, the glucocorticoid and other drugs are mainly used in the acute stage, the drugs for promoting uric acid excretion and inhibiting uric acid generation are mainly used in the chronic stage and the interstitial stage, the patient can control the disease progress and promote the metabolic rate of uric acid after taking the febuxostat and the non-steroidal anti-inflammatory drug, but the red swelling and hot pain degree of the joint of part of the patient is aggravated after taking the drugs, and obvious adverse reactions such as liver and kidney function damage, drug allergy, bone marrow and immune inhibition and the like easily occur after long-term taking of the drugs, even the patient induces digestive tract ulcer or digestive tract hemorrhage and the like. After the drug is stopped, symptoms are easy to relapse, and the clinical curative effect is seriously influenced, so that the development of a drug which has obvious curative effect on the gouty arthritis and less side effect becomes the key point of the modern medical research.
Disclosure of Invention
Aiming at the problems in the prior art, the invention aims to provide the Dai medicine composition for external use for treating gouty arthritis, the raw materials of the Dai medicine composition can be synergized, the safety is high, and the curative effect on treating gouty arthritis is obvious.
The invention relates to an external Dai medicine composition for treating gouty arthritis, which is prepared from the following raw materials in parts by weight: 15-35 parts of swertia mileensis, 10-30 parts of turmeric, 10-30 parts of anemone, 15-35 parts of eclipta alba and 10-30 parts of plantain.
Preferably, the externally applied Dai medicine composition is prepared from the following raw materials in parts by weight: 20 parts of tinospora sinensii, 20 parts of turmeric, 20 parts of anemone, 20 parts of eclipta alba and 20 parts of plantain.
The invention also provides a preparation method of the externally applied Dai medicine composition for treating gouty arthritis, which comprises the following steps:
s1, weighing the Tinospora sinensis, the turmeric, the anemone, the eclipta and the plantain according to the parts by weight, mixing uniformly, crushing into fine powder, and sieving to obtain Dai medicine mixed powder A;
s2, mixing the obtained Dai medicine mixed powder A with a pharmaceutically acceptable paste matrix to obtain a paste, and obtaining the Dai medicine composition for external use.
Preferably, in step S1, the fine powder is sieved by a 200-250 mesh sieve.
Preferably, the ointment base is vaseline, cataplasm or polyethylene glycol 400.
The invention also aims to provide application of the externally applied Dai medicine composition as an active ingredient in treating gouty arthritis.
The compatibility principle of the externally used Dai medicine composition is explained as follows:
the invention summarizes an effective empirical prescription for treating the symptoms of gouty arthritis on the basis of long-term clinical evidence, and the effective prescription comprises the following components: the medicinal materials comprise swertia mileensis, turmeric, wind-evil dispelling grass, eclipta alba and plantain, and the pharmacological activities of the medicinal materials are as follows: the green ox gall: is dry root tuber of Tinospora cordifolia of Menispermaceae, has cold property, bitter taste, no channel tropism, and has effects of clearing heat, detoxicating, relieving sore throat, and relieving pain. Turmeric: is dried rhizome of Curcuma longa of Zingiberaceae, and has the following properties and tastes: pungent, bitter and warm herbs enter liver and spleen meridians, and have the actions of activating blood and qi, dispelling wind and alleviating pain, so it is indicated for chest and hypochondriac pain, amenorrhea and abdominal pain, and arthralgia due to wind-cold-dampness caused by qi stagnation and blood stasis. Nature and taste: sweet, sour and cold. It enters kidney and liver meridians. Has effects of nourishing liver and kidney, cooling blood and stopping bleeding. Can be used for treating liver and kidney yin deficiency, odontoseisis, premature gray hair, giddiness tinnitus, soreness of waist and knees, blood heat hematemesis due to yin deficiency, epistaxis, hematuria, bloody dysentery, metrorrhagia, metrostaxis, and traumatic hemorrhage. Wind-weed removal: sweet and light taste, smelly smell and mild nature, and has the effects of dispelling wind, removing dampness, promoting blood circulation and removing blood stasis. Plantain herb: is dried or fresh whole plant before plantago. Cold in nature; sweet in taste; it enters liver, kidney, lung and small intestine meridians. Has effects of clearing heat, promoting urination, eliminating phlegm, cooling blood, and removing toxic substance, and can be used for treating edema oliguria, heat stranguria, summer-heat dampness dysentery, phlegm heat cough, hematemesis, epistaxis, carbuncle, swelling, and sore.
The invention has the following beneficial effects:
the Dai medicine composition for external use selects the Tinospora sinensis as a main medicine, and the Tinospora sinensis is bitter in taste and cool in nature and has the effects of inducing diuresis to alleviate edema, dispelling wind and relieving pain, and relaxing muscles and tendons to activate blood; the plantain herb and the eclipta alba are selected as auxiliary drugs, wherein the plantain herb is cool in nature and enters an earth tower to have the functions of inducing diuresis, removing jaundice, detoxifying and reducing swelling, the active ingredient plantain herb extract can regulate and control the expression of inflammatory factors, the eclipta alba is cool in nature and enters a water tower to have the functions of clearing away fire, detoxifying, relieving spasm and relieving pain, the active ingredient eclipta alba extract has better anti-inflammatory and analgesic effects, and the plantain herb and the eclipta alba are used as the auxiliary drugs to assist the main drugs to enhance the curative effect; turmeric is selected as an inhibitor, the turmeric has bitter and slightly spicy flavor and warm nature, is used in soil, water and wind towers, has the functions of clearing away heat and toxic materials, promoting blood circulation to stop pain, promoting the circulation of qi and removing blood stasis, and restricts the cold and cool nature of monarch and minister drugs, and the corresponding active ingredient curcumin can inhibit the survival and proliferation genes of partial cells by inhibiting NF-k B and related regulatory gene expression, play the role of inhibiting the proliferation of various cells, and inhibit the proliferation of the cells and induce the apoptosis of the cells by blocking the cell cycle; the wind-evil dispelling herb is selected as a blending medicine, is sweet and light in flavor, smelly in smell and mild in nature, has the effects of dispelling wind, eliminating dampness, promoting blood circulation and removing blood stasis, and can blend the medicines. The Dai medicinal materials with different components and different medicinal properties are scientifically matched, and the Dai medicinal materials have the effects of promoting blood circulation, removing blood stasis, dredging collaterals, relieving swelling, resisting inflammation, relieving pain, relaxing tendons and activating collaterals, and can have a good clinical effect of treating tissue swelling caused by gouty arthritis. The invention adopts an external method to treat local inflammatory reaction, can be absorbed by skin, ensures that the effective concentration of local medicaments is obviously higher than blood concentration, exerts obvious curative effect and has safety and small side effect.
Detailed Description
The technical solution of the present invention will be further explained with reference to the following specific embodiments.
Example 1
The Dai medicine composition for external use for treating gouty arthritis comprises the following crude drugs: 20g of swertia mileensis, 20g of turmeric, 20g of anemone, 20g of eclipta alba and 20g of plantain.
Example 2
A Dai medicine composition for external use for treating gouty arthritis comprises crude drugs: 20g of swertia mileensis, 30g of turmeric, 15g of anemone, 15g of eclipta alba and 20g of plantain.
Example 3
A Dai medicine composition for external use for treating gouty arthritis comprises crude drugs: 15g of swertia mileensis, 15g of turmeric, 30g of anemone, 25g of eclipta alba and 20g of plantain.
Example 4
A Dai medicine composition for external use for treating gouty arthritis comprises crude drugs: 35g of swertia mileensis, 10g of turmeric, 10g of anemone, 35g of eclipta alba and 10g of plantain.
Example 5
A Dai medicine composition for external use for treating gouty arthritis comprises crude drugs: 20g of swertia mileensis, 10g of turmeric, 25g of anemone indica, 15g of eclipta alba and 30g of plantain herb.
In this embodiment, the paste matrix is a carrier of the Dai medicine, and can be coated on a mount material to prepare an external preparation after being mixed with the Dai medicine. In this embodiment, the exemplified ointment base can be, but not limited to, vaseline, cataplasma or polyethylene glycol 400, and meanwhile, in this embodiment, the practical exemplified ointment base is cataplasma, which has a large drug-loading capacity, is particularly suitable for a traditional Chinese medicine extract, has good biocompatibility with skin, is air-permeable, sweat-resistant, and has no genital sensitivity and irritation, and has good drug release performance and convenient use. The external Dai medicine composition for treating gouty arthritis provided by the invention has the advantages that all the used raw materials conform to the regulations of the people's republic of China and the national drug code, the medicine sources are safe and reliable, no toxic or side effect exists, the treatment effect on gouty arthritis is good, and the medicine composition is harmless to human bodies.
Experiment of drug effect
1.1 grouping and administration of Experimental animals
72 male SD rats with weight (about 200g) and clean grade are normally bred for one week, and then are randomly divided into 6 groups according to the weight, namely a normal control group, a model group, a sitalin (diclofenac sodium gel) group, a Dai medicine composition external application group, a pyretic arthralgia powder group and a gout powder group. Each group has 12. The breeding is carried out in cages, and water is freely drunk, so that the conditions of all groups are equal. Except for the normal control group, all the rats in other groups are injected with 0.1ml of Freund's complete adjuvant after the conventional disinfection of the right hind foot plantar part, and the injection point is preferably obvious white bubbles around the injection point, so that the molding success is realized when the arthritis index value of the rat is more than or equal to 6 on the 12 th day after the inflammation. After each group of modeling succeeds, the medicine is respectively administered: the nataline group is externally coated with a nataline ointment, the thickness of the nataline ointment is about 2mm, the nataline ointment uniformly covers the surface of a molding joint, and the time is 2 times every day; the heat arthralgia dissipating group is an external heat arthralgia dissipating group, has a thickness of about 2mm, and uniformly covers the surface of a molded joint for 2 times a day; the TONGFENG powder group is topical TONGFENG powder with thickness of about 2mm, and uniformly covers the surface of the molded joint for 2 times per day; the Dai medicine composition was applied topically to the prepared ointment according to this example 1, and the ointment was applied to the surface of the molded joint uniformly 2 times a day. The model group and the normal control group were administered with 3ml of physiological saline by intragastric administration once a day. The above groups were administered continuously for 14 days.
1.2 preparation of sodium urate solution
Weighing 500mg of sodium urate, adding 9mL of normal saline and 1mL of Tween-80, heating and stirring to dissolve, and preparing 10mL of sodium urate solution.
1.3 preparation of acute gouty arthritis model of rat
After 1h of administration, a Coderre method is adopted for modeling, a rat is subjected to intraperitoneal injection by using 7% chloral hydrate (350mg/kg), hairs at the position of a right ankle joint are cut off after anesthesia, the ankle joint is bent slightly, after local disinfection by medical alcohol, a No. 6 needle of a TB syringe is inserted into the inner side of a tibial muscle bond from the 45-degree direction of the right ankle joint of the tested rat, after the falling feeling is felt, 0.2mL of sodium urate solution is injected into the ankle joint cavity of the rat to prepare an acute gouty arthritis model, and 0.2mL of physiological saline is injected into the ankle joint cavity of the rat in a blank group.
2. Taking materials
The medication was continued for 21 days, and the rats in each group were fasted and not deprived of water at the night of the last administration. The materials are taken the next day, the abdominal cavity is cut after rat abdominal cavity injection anesthesia is carried out by urethane, abdominal cavity organs are separated by surgical instruments, the abdominal aorta is exposed and ligated, then abdominal aorta puncture is carried out by a 5ml syringe, and about 3-5 ml of arterial blood is extracted. Finally, the rats were sacrificed. Marking 6 groups of blood, centrifuging for 10 minutes at 2000r/min on a centrifuge, and taking supernate to be tested. Taking the left hind ankle joint, embedding in normal paraffin, slicing, HE staining, and observing with a light microscope.
3. Detection of indicators
3.1 detection of various inflammation indicators
TNF-alpha (tumor necrosis factor alpha), CRP (rat C-reactive protein) and IL-6 (interleukin 6) levels in gouty arthritis rat serum are detected by an enzyme-linked immunosorbent assay (ELISA) method according to the kit specification, and the levels of TNF-alpha, CRP and IL-6 in adjuvant arthritis rat serum are detected. The experimental data are expressed as mean ± standard deviation (SX ±), and the statistical analysis adopts a variance analysis method of rank sum test and repeated measurement. The results of the processing using the SPSS13.0 statistical software are shown in table 1 below.
TABLE 1 Effect on serum TNF-a, CRP and IL-6 levels in gouty arthritis rats (x earths, n ═ 10)
3.2 Effect on gouty arthritis rat serum UA levels
UA is an important biochemical index for detecting gouty arthritis and is an important factor for gout formation, the effect of each administration group on treating gouty arthritis is evaluated by detecting the UA level in blood plasma in the experiment, and the result is shown in the following table 2.
Table 2 effect of each dosing group on UA levels in serum of rats as a model of gouty arthritis (x ± S, n ═ 10)
And (4) experimental conclusion: compared with the normal control group, the model group has increased IL-6, TNF-alpha, CRP and inflammation index level (P < 0.05). Compared with the model group, the IL-6, TNF-alpha and CRP expression levels of the hibioline (diclofenac sodium gel) group and the Dai medicine composition external application group are reduced (P <0.05), and the differences of the Dai medicine composition external application group and the above inflammatory factors, the hibiline (diclofenac sodium gel) group and the febrile rheumatism group have no statistical significance (P > 0.05). Uric acid was significantly increased in the model group compared to the normal group (P < 0.05). Compared with a model group, the Dai medicine composition has the advantages that the Uric Acid (UA) of the external application group is reduced (P is less than 0.05), and the difference has statistical significance. Compared with the model group (P is more than 0.05), the differences of the uric acid in the sitagliptin (diclofenac sodium gel) group and the febrile rheumatism powder group have no statistical significance.
The above description is only for the preferred embodiment of the present invention, but the scope of the present invention is not limited thereto, and any person skilled in the art should be considered to be within the technical scope of the present invention, and the technical solutions and the inventive concepts thereof according to the present invention should be equivalent or changed within the scope of the present invention.
Claims (6)
1. The externally applied Dai medicine composition for treating gouty arthritis is characterized by being prepared from the following raw materials in parts by weight: 15-35 parts of swertia mileensis, 10-30 parts of turmeric, 10-30 parts of anemone, 15-35 parts of eclipta alba and 15-35 parts of plantain.
2. The Dai medicine composition for external use for treating gouty arthritis according to claim 1, which is prepared from the following raw materials in parts by weight: 20 parts of tinospora cordifolia, 20 parts of turmeric, 20 parts of anemone, 20 parts of eclipta alba and 20 parts of plantain.
3. A method for preparing the dai medicine composition for external use for treating gouty arthritis according to claim 1 or 2, which comprises the following steps:
s1, weighing the Tinospora sinensis, the turmeric, the anemone, the eclipta and the plantain according to the parts by weight, mixing uniformly, crushing into fine powder, and sieving to obtain Dai medicine mixed powder A;
s2, mixing the obtained Dai medicine mixed powder A with a pharmaceutically acceptable paste matrix to obtain a paste, and obtaining the Dai medicine composition for external use.
4. The method for preparing the Dai medicine composition for external use for treating gouty arthritis according to claim 3, wherein in step S1, the fine powder is sieved by a 200-250 mesh sieve.
5. The method for preparing the Dai medicine composition for external use for treating gouty arthritis according to claim 3, wherein the paste matrix is vaseline, cataplasm or polyethylene glycol 400.
6. The use of the Dai medicine composition for external use as claimed in claim 1 or 2, as an active ingredient in the treatment of gouty arthritis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210200870.8A CN114917309A (en) | 2022-03-03 | 2022-03-03 | Dai medicine composition for external use for treating gouty arthritis and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210200870.8A CN114917309A (en) | 2022-03-03 | 2022-03-03 | Dai medicine composition for external use for treating gouty arthritis and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114917309A true CN114917309A (en) | 2022-08-19 |
Family
ID=82804667
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210200870.8A Withdrawn CN114917309A (en) | 2022-03-03 | 2022-03-03 | Dai medicine composition for external use for treating gouty arthritis and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114917309A (en) |
-
2022
- 2022-03-03 CN CN202210200870.8A patent/CN114917309A/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103463297B (en) | A kind of Chinese medicine composition for the treatment of eczema scrotum and its production and use | |
| CN108310320A (en) | A kind of externally applied drug and preparation method thereof for treating gout | |
| CN102579701A (en) | Compound dandelion decoction | |
| CN104258278A (en) | Gushangling (for bone injury) spray | |
| CN109432269A (en) | A kind of Chinese medicine composition and preparation method, purposes | |
| CN104815318A (en) | Traditional Chinese medicine preparation for treating gout | |
| CN102430097A (en) | Chinese medicine for treating vitiligo | |
| CN112023006B (en) | A topical Chinese medicinal composition for treating rheumatism, and its preparation method and application | |
| CN114917309A (en) | Dai medicine composition for external use for treating gouty arthritis and application | |
| CN110478416A (en) | The composition and its preparation method and application for treating rheumatic rheumatoid arthritis | |
| CN105412596A (en) | Traditional Chinese medicine composition for treating liver tumors and preparation method thereof | |
| CN109157635B (en) | Honeysuckle stem compound with anti-depression effect and preparation method and application thereof | |
| CN116549522B (en) | Application of traditional Chinese medicine composition in gout | |
| CN113648349B (en) | A topical Chinese medicinal composition for preventing and treating rheumatism and pyretic arthralgia, and its preparation method | |
| CN107510765A (en) | A kind of Chinese medicine composition for treating phlegm-blood stasis numbness network type rheumatic Bi syndrome and preparation method thereof | |
| CN105561274A (en) | Traditional Chinese medicine preparation for esophagus cancer and preparation method thereof | |
| CN117018069A (en) | Externally applied Zhuang medicine composition for treating rheumatic arthritis and preparation method and application thereof | |
| CN116196359A (en) | Traditional Chinese medicine wine for treating rheumatism and traumatic injury and preparation method thereof | |
| CN101366887B (en) | Externally washing traditional Chinese medicine preparation for detumescence and dissipation blood stasis | |
| CN103550337B (en) | Traditional Chinese medicine composition for treating female irregular menstruation and preparation method thereof | |
| CN114470122A (en) | A Chinese medicinal composition for treating syphilis, and its preparation method | |
| CN116763834A (en) | Traditional Chinese medicine composition and preparation for treating arthralgia as well as preparation method and application of traditional Chinese medicine composition and preparation | |
| CN113925846A (en) | Black plaster suitable for acute soft tissue injury and preparation method thereof | |
| CN115531501A (en) | Application of Jinfeng diabetes compound preparation in preparation of medicine for treating non-alcoholic fatty liver disease | |
| CN114588233A (en) | Composition for treating acute gout |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20220819 |
|
| WW01 | Invention patent application withdrawn after publication |